ANGOSTURA
12.2.2020 18:47:05 CET | Business Wire | Press release
The House of Angostura® has announced that world-renowned Trinidadian-born DJ, music producer and entrepreneur Christopher “Jillionaire” Leacock will add some star quality to the judging panel, and the celebration, at this year’s Angostura Global Cocktail Challenge. This biannual event, celebrates its 10th anniversary in 2020 and brings together bartenders worldwide for the chance to become the global champion. The Angostura® Global Cocktail Challenge Finals takes place on February 22 in Trinidad & Tobago, ahead of the greatest show on earth, Trinidad & Tobago Carnival.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200212005699/en/
Peter Sandström, CEO of Angostura® , comments: “The Angostura® Global Cocktail Challenge is the 10th anniversary of the competition and we wanted to do something special to mark the occasion. Partnering with Jillionaire made so much sense as his roots are inherently connected to the House of Angostura® . He has a strong understanding of Angostura’s place at the heart of Trinidad & Tobago culture, enormous passion for locally inspired music and drinks and his global following helps elevate the competition to showcase the extraordinary talents of our competitors to an international audience.”
The nine finalists of the Angostura® Global Cocktail Competition 2020 are: Shana Rajahram (Trinidad & Tobago), Marv Cunningham (The Bahamas), Chad Lawrence (Canada), Gustavo Costa (Brazil), Mike Jordhoy (France), Rohan Massie (Australia), Simon Dacey (United Kingdom), Vasile Dorofeev (Dubai) and Agung Satria (Vietnam).
Jillionaire, best known for his contributions to Major Lazer, an American electronic music group, brings a keen interest and understanding of the bar industry as part-owner of Clyde’s, a Trinidadian cocktail bar in Brooklyn, New York. He is well prepared to see the nine finalists compete, as they aim to wow the judges with cocktail prowess.
Jillionaire shares why he’s proud to join the Angostura® Global Cocktail Challenge judging panel: “I am a proud supporter of Trinidadian culture and have a personal interest in cocktail culture and one of our island’s biggest exporter - Angostura® . Angostura’s historic bitters are known the world over. I’m keen to shine a light on our celebrated rum and amaro which capture the flavours of Trinidad & Tobago. Whoever goes on to win the competition, will not only be representing Angostura® , they’ll be representing our island on the world stage, something I take seriously.”
Angostura Global Cocktail Competition Master of Ceremonies and Judging Panel
Jillionaire will join head judge and James Beard Award-winning beverage professional, Maxwell Britten. Other judges include Eryn Reece, Bar Director at The Wooly Public, Joe Schofield, co-owner of Schofield’s Bar, Angostura® Chief Brand Educator, Raymond Edwards, and the reigning Angostura® Global Cocktail Challenge Champion, Raymond Letoa. Hospitality industry veteran Ms Franky Marshall will serve as Master of Ceremonies. After the competition, Jillionaire will lead the after-party celebrations, performing a curated DJ set.
The winning bartender will receive the coveted title of “Angostura® Global Cocktail Challenge (AGCC) Champion,” a cash prize of US$10,000 and a two-year contract as the Angostura® Global Brand Ambassador for ANGOSTURA® aromatic bitters, ANGOSTURA® orange bitters, Angostura® Rums and Amaro di ANGOSTURA® , as well as the opportunity to revisit Angostura’s home in Trinidad & Tobago to serve as a judge at the next edition of the competition.
For more information about the competition, visit www.AngosturaGlobalCocktailChallenge.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200212005699/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom